Publications by authors named "E Assenat"

Claim this Profile
R
Reply to: Oxaliplatin Dosing and Toxicity: A Cautionary Perspective on Efficacy.
Eric Assenat, Pierre Senesse

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.
Eric Assenat, Meher Ben Abdelghani, Sophie Gourgou, Hervé Perrier, Faiza Khemissa Akouz

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib for Hepatocellular Carcinoma in Real-World Practice (CLERANCE): A Prospective, Interventional Study.
François Villeret, Mohamed Bouattour, Jean-Frédéric Blanc, Jean-Marie Péron, Marilyne Debette-Gratien, Eric Assenat

Liver Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study.
Iona Campo-Le-Brun, Emma Grapinet, Valerie Aurillac, Antoine Hollebecque, Pauline Parent, Eric Assenat

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GABRINOX-2 protocol: a French, prospective, multicentre, randomised phase II trial evaluating gemcitabine/nab-paclitaxel followed by FOLFIRINOX versus FOLFIRINOX alone as first-line treatment for metastatic pancreatic cancer.
Fabienne Portales, Sophie Gourgou, Catherine Fiess, Fanny Salasc, Eric Assenat

BMJ Open· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis